var docs;if (!docs) docs =[]; docs["82"]={"8200":"<p><b>Title</b> Benzodiazepines / Kava Kava</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Kava Kava may enhance the adverse/toxic effect of Benzodiazepines. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Caution patients about the potential for increased benzodiazepine actions if kava is used together with a benzodiazepine. Monitor response to concurrent use closely.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam, Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n</div> \n<p><b>Discussion</b> A case-report describes a patient receiving the benzodiazepine alprazolam who developed a lethargic and disoriented state leading to hospitalization three days after taking kava bought at a local health food store.<sup>1</sup> The patient's symptoms resolved over several hours.<br><br>A proposed mechanism of the potential interaction is enhancement of the benzodiazepine-mediated GABA activity by kava.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. <i>Ann Intern Med</i>. 1996;125(11):940-941. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8967683\">[PubMed 8967683]</a></p>\n<p>2. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. <i>Drugs</i>. 2009;69(13):1777-1798. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19719333\">[PubMed 19719333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8201":"<p><b>Title</b> Anti-Parkinson Agents (Dopamine Agonist) / Kava Kava</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Kava Kava may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Caution should be used in patients receiving concomitant therapy. A diminished clinical response to dopamine agonists or extrapyramidal type reaction may be evident in some patients.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine, Bromocriptine, Levodopa, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n</div> \n<p><b>Discussion</b> A case report described a Parkinson disease patient receiving levodopa (500 mg daily) started on Kavasporal forte (150 mg kava extract twice daily) for complaints of inner tension. Within 10 days of starting the kava product the patient noted a pronounced increase in the duration and number of her daily “off” periods, but her Parkinson disease returned to a baseline level of control after stopping the Kavasporal forte for two days.<sup>1</sup> Two additional case reports describe extrapyramidal symptoms (EPS)-type reactions in patients 45-90 minutes after Laitan (100 mg kava extract) administration. Both cases resolved in approximately 45 minutes after biperiden (5 mg IV) administration.<sup>1</sup> A final case report described an EPS-type reaction in a patient after taking Kavasporal forte (150 mg kava extract, three times daily) for four days that was resolved with administration of biperiden (5 mg IV).<sup>1</sup><br><br>A proposed mechanism of the potential interaction is antagonism of CNS dopamine receptors by constituents in the kava supplement.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. <i>J Neurol Neurosurg Psychiatry</i>. 1995;58(5):639-640. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7745421\">[PubMed 7745421]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8202":"<p><b>Title</b> PARoxetine / Kava Kava</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Kava Kava may enhance the adverse/toxic effect of PARoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Caution patients about the possible increased risk for adverse CNS effects and other adverse reactions if kava is used together with paroxetine. Monitor response to concurrent use closely.</p> \n<p><b>Discussion</b> A case report described a patient receiving paroxetine (30 mg daily), kava kava, and valerian root for depression resulting in several hospital admissions for ataxia, lethargy, slurred speech, confusion, and urinary incontinency. Upon discontinuation of the kava kava and valerian root the patient returned to baseline; symptoms then rebounded when the kava kava was restarted.<sup>1</sup><br><br>A proposed mechanism of the potential interaction is additive adverse effects/toxicities.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rubin D, McGovern B, Kopelman RI. Back to basics. <i>Am J Med</i>. 2006;119(6):482-483. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16750959\">[PubMed 16750959]</a></p>\n<p>2. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. <i>Drugs</i>. 2009;69(13):1777-1798. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19719333\">[PubMed 19719333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8203":"<p><b>Title</b> Albendazole / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease serum concentrations of the active metabolite(s) of Albendazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of diminished clinical response to albendazole if used together with phenytoin. The antiepileptics carbamazepine and phenobarbital appear to interact similarly, making them less desirable as alternatives. The degree to which other antiepileptics would interact with albendazole is uncertain, but other antiepileptics are not considered to be as capable of enzyme induction as phenytoin, carbamazepine, and phenobarbital.</p> \n<p><b>Discussion</b> The AUC of the active (+)-albendazole sulfoxide (ASOX) and (-)-ASOX metabolites were approximately 66-77% lower with concurrent phenytoin (200-300 mg/day for at least 3 months) in a study comparing albendazole pharmacokinetics in individuals with neurocysticercosis being treated with albendazole (7.5 mg/kg every 12 hours for 8 days) and not taking concurrent antiepileptics (controls; n=9) to those in subjects who were receiving concurrent phenytoin (n=9).<sup>1</sup> Maximum serum concentrations (Cmax) and half-lives of (+)-ASOX and (-)-ASOX were also approximately 66-77% and 53-56% lower, respectively, with concurrent phenytoin. Several subjects in both groups (4/9 controls and 5/9 phenytoin recipients) were also taking dexamethasone. Though dexamethasone is generally regarded as an inducer of CYP3A4, suggesting a potential for dexamethasone to have an independent effect on albendazole/ASOX concentrations, one prior study found that dexamethasone increased plasma concentrations of albendazole by approximately 50%.<sup>2</sup><br><br>The mechanism for this interaction is most likely induction of the CYP3A4-mediated metabolism of albendazole and/or ASOX by phenytoin, which is a well-documented inducer of CYP3A4 and other drug-metabolizing enzymes, though induction of other enzymes responsible for albendazole/ASOX metabolism or elimination may also contribute to the interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. <i>Ther Drug Monit</i>. 2002;24(3):338-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021623\">[PubMed 12021623]</a></p>\n<p>2. Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. <i>J Neurol</i>. 1990;237(5):279-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2230841\">[PubMed 2230841]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8204":"<p><b>Title</b> Albendazole / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease serum concentrations of the active metabolite(s) of Albendazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of diminished clinical response to albendazole if used together with carbamazepine. The antiepileptics phenytoin and phenobarbital appear to interact similarly, making them less desirable as alternatives. The degree to which other antiepileptics would interact with albendazole is uncertain, but other antiepileptics are not considered to be as capable of enzyme induction as phenytoin, carbamazepine, and phenobarbital.</p> \n<p><b>Discussion</b> The AUC of the active (+)-albendazole sulfoxide (ASOX) and (-)-ASOX metabolites were approximately 49-68% lower with concurrent carbamazepine (600-1200 mg/day for at least 3 months) in a study comparing albendazole pharmacokinetics in individuals with neurocysticercosis being treated with albendazole (7.5 mg/kg every 12 hours for 8 days) and not taking concurrent antiepileptics (controls; n=9) to those in subjects who were receiving concurrent carbamazepine (n=9).<sup>1</sup> Maximum serum concentrations (Cmax) and half-lives of (+)-ASOX and (-)-ASOX were also approximately 49-55% and 49% lower, respectively, with concurrent carbamazepine. Several subjects in both groups (4/9 controls and 3/9 carbamazepine recipients) were also taking dexamethasone. Though dexamethasone is generally regarded as an inducer of CYP3A4, suggesting a potential for dexamethasone to have an independent effect on albendazole/ASOX concentrations, one prior study found that dexamethasone increased plasma concentrations of albendazole by approximately 50%.<sup>2</sup><br><br>The mechanism for this interaction is most likely induction of the CYP3A4-mediated metabolism of albendazole and/or ASOX by carbamazepine, which is a well-documented inducer of CYP3A4 and other drug-metabolizing enzymes, though induction of other enzymes responsible for albendazole/ASOX metabolism or elimination may also contribute to the interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. <i>Ther Drug Monit</i>. 2002;24(3):338-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021623\">[PubMed 12021623]</a></p>\n<p>2. Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. <i>J Neurol</i>. 1990;237(5):279-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2230841\">[PubMed 2230841]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8205":"<p><b>Title</b> Albendazole / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PHENobarbital may decrease serum concentrations of the active metabolite(s) of Albendazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of diminished clinical response to albendazole if used together with phenobarbital. The antiepileptics phenytoin and carbamazepine appear to interact similarly, making them less desirable as alternatives. The degree to which other antiepileptics would interact with albendazole is uncertain, but other antiepileptics are not considered to be as capable of enzyme induction as phenytoin, carbamazepine, and phenobarbital.</p> \n<p><b>Discussion</b> The AUC of the active (+)-albendazole sulfoxide (ASOX) and (-)-ASOX metabolites were approximately 60-72% lower with concurrent phenobarbital (100-300 mg/day for at least 3 months) in a study comparing albendazole pharmacokinetics in individuals with neurocysticercosis being treated with albendazole (7.5 mg/kg every 12 hours for 8 days) and not taking concurrent antiepileptics (controls; n=9) to those in subjects who were receiving concurrent phenobarbital (n=5).<sup>1</sup> Maximum serum concentrations (Cmax) and half-lives of (+)-ASOX and (-)-ASOX were also approximately 50-65% and 39-51% lower, respectively, with concurrent phenobarbital. Subjects in both groups (4/9 controls and 1/5 phenobarbital recipients) were also taking dexamethasone. Though dexamethasone is generally regarded as an inducer of CYP3A4, suggesting a potential for dexamethasone to have an independent effect on albendazole/ASOX concentrations, one prior study found that dexamethasone increased plasma concentrations of albendazole by approximately 50%.<sup>2</sup><br><br>The mechanism for this interaction is most likely induction of the CYP3A4-mediated metabolism of albendazole and/or ASOX by phenobarbital, which is a well-documented inducer of CYP3A4 and other drug-metabolizing enzymes, though induction of other enzymes responsible for albendazole/ASOX metabolism or elimination may also contribute to the interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. <i>Ther Drug Monit</i>. 2002;24(3):338-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021623\">[PubMed 12021623]</a></p>\n<p>2. Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. <i>J Neurol</i>. 1990;237(5):279-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2230841\">[PubMed 2230841]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8206":"<p><b>Title</b> Tasimelteon / CYP1A2 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of tasimelteon and strong CYP1A2 inhibitors.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Strong) Interacting Members</b> FluvoxaMINE</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, fluvoxamine (50 mg once daily for 7 days) increased the tasimelteon (5 mg single oral dose) maximum serum concentration and AUC 2.3- and 6.5-fold, respectively.<sup>1,2</sup> <br><br>Tasimelteon prescribing information recommends avoiding the combination of tasimelteon and strong CYP1A2 inhibitors (such as fluvoxamine) due to the large increase in tasimelteon exposure and increased risk of adverse reactions<sup>1</sup><br><br>The suspected primary mechanism of this interaction is fluvoxamine inhibition of CYP1A2-mediated tasimelteon metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hetlioz (tasimelteon) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; December 2014.</p>\n<p>2. Ogilvie BW, Torres R, Dressman MA, Kramer WG, Baroldi P. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. [published online April 6, 2015]. <i>J Clin Pharmacol</i>. doi: 10.1002/jcph.507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25851638\">[PubMed 25851638]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8207":"<p><b>Title</b> Tasimelteon / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of tasimelteon and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, rifampin (600 mg once daily for 10 days) decreased the tasimelteon (20 mg single oral dose) maximum serum concentration and AUC 83% and 89%, respectively.<sup>1,2</sup> <br><br>Tasimelteon prescribing information recommends avoiding the combination of tasimelteon and strong CYP3A4 inducers (such as rifampin) due to the large decrease in tasimelteon exposure and potential for reduced tasimelteon efficacy.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated tasimelteon metabolism. Rifampin induction of other enzymes that mediate tasimelteon metabolism (e.g., CYP1A2, 2C19) may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hetlioz (tasimelteon) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc; December 2014.</p>\n<p>2. Ogilvie BW, Torres R, Dressman MA, Kramer WG, Baroldi P. Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. [published online April 6, 2015]. <i>J Clin Pharmacol</i>. doi: 10.1002/jcph.507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25851638\">[PubMed 25851638]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8208":"<p><b>Title</b> Warfarin / Ascorbic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ascorbic Acid may diminish the anticoagulant effect of Warfarin. Ascorbic Acid may decrease the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> More frequent anticoagulation monitoring may be necessary upon initiation of warfarin therapy with concomitant ascorbic acid. An increase in warfarin dosing or discontinuation of ascorbic acid may warrant consideration based on individual patient’s anticoagulation status.</p> \n<p><b>Discussion</b> Several published case reports describe patients who developed an apparent relative resistance to warfarin that was attributed to ingestion of ascorbic acid.<sup>1,2,3,4,5</sup> Discontinuation of the ascorbic acid was associated with an apparent improvement in warfarin sensitivity, with increasing INR/PT values and/or decreasing warfarin dose-requirements. While most cases involved oral ingestion of ascorbic acid (as supplements for general health status or prevention of viral illness), one case involved the one-time intravenous administration of a chelating treatment containing 7 g of vitamin C.<sup>5</sup><br><br>In contrast, a case series in which 5 warfarin-treated patients were given vitamin C supplementation (1 g/day) for 2 weeks reported no significant change in PT times associated with vitamin C supplementation.<sup>6</sup> High-dose vitamin C (3 g/day, 5 g/day, and 10 g/day) was similarly not associated with any change in warfarin effects in a study of healthy volunteers, despite a 2-40% increase (average increase of 17.5%) in plasma warfarin concentrations.<sup>7</sup> A study in dogs also reported no change in clotting factor pharmacokinetics with concurrent ascorbic acid supplementation.<sup>8</sup><br><br>The exact mechanism for this reported interaction is unclear. That higher-dose ascorbic acid may reduce warfarin concentrations suggests a possible pharmacokinetic mechanism,<sup>7</sup> but the reported lack of any association between changes in warfarin concentrations and observed pharmacodynamic effects makes it unclear if such pharmacokinetic changes are sufficient to account for the changes detailed in reported cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sattar A, Willman JE, Kolluri R. Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review. <i>Am J Health Syst Pharm</i>. 2013;70(9):782-786. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23592361\">[PubMed 23592361]</a></p>\n<p>2. Rosenthal G. Interaction of ascorbic acid and warfarin. <i>JAMA</i>. 1971;215(10):1671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107696\">[PubMed 5107696]</a></p>\n<p>3. Didichen J. The effect of ascorbic acid given to patients on chronic anticoagulant therapy. <i>Boll Soc Ital Cardiol</i>. 1973;18(7):690-692. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4807159\">[PubMed 4807159]</a></p>\n<p>4. Smith EC, Skalski RJ, Johnson GC, Rossi GV. Interaction of ascorbic acid and warfarin. <i>JAMA</i>. 1972;221(10):1166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4679014\">[PubMed 4679014]</a></p>\n<p>5. Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. <i>Pharmacotherapy</i>. 2002;22(8):1067-1069. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12173793\">[PubMed 12173793]</a></p>\n<p>6. Hume R, Johnstone JM, Weyers E. Interaction of ascorbic acid and warfarin. <i>JAMA</i>. 1972;219(11):1479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5066913\">[PubMed 5066913]</a></p>\n<p>7. Feetam CL, Leach RH, Meynell MJ. Lack of a clinically important interaction between warfarin and ascorbic acid. <i>Toxicol Appl Pharmacol</i>. 1975;31(3):544-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1145638\">[PubMed 1145638]</a></p>\n<p>8. Weintraub M, Griner PF. Warfarin and ascorbic acid: lack of evidence for a drug interaction. <i>Toxicol Appl Pharmacol</i>. 1974;28(1):53-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4855406\">[PubMed 4855406]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8209":"<p><b>Title</b> Dabigatran Etexilate / Clarithromycin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations for management of this interaction may be different for those with atrial fibrillation receiving prophylaxis vs. those being treated for deep venous thrombosis or pulmonary embolism.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling.</p></li>\n <li><p><b>Renal Function</b>: The clinical significance and recommended management of this interaction both increase considerably in patients with moderate (CrCl 30-50 mL/min) or severe (CrCl 15-30 mL/min) renal dysfunction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The recommendations for management of this potential drug interaction depend on the indication for dabigatran use, patient renal function, and country specific labeling recommendations. This combination should be used with caution, and patients receiving dabigatran with concurrent clarithromycin should be monitored more closely for evidence of bleeding. Patients over 75 years-of-age and those with impaired renal function may be at greatest risk for a significant interaction. <br><br>The U.S. prescribing information specifically recommends avoiding concurrent use of dabigatran with any P-glycoprotein inhibitor (such as clarithromycin) in patients with severe renal dysfunction (CrCl 15-30 mL/min) when dabigatran is used for atrial fibrillation, and in patients with moderate renal dysfunction (CrCl less than 50 mL/min) when dabigatran is used for the treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE), or for prophylaxis of DVT/PE following hip replacement.</p> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with dabigatran (49.65% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, rivaroxaban or apixaban), concurrent use of clarithromycin or erythromycin was associated with a 40% decrease in the incidence rate ratio for major bleeding.<sup>1</sup> Of note, several other combinations examined in this cohort study yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>The dabigatran AUC and maximum serum concentration (Cmax) were increased by an average of 49% and 60%, respectively, with concurrent clarithromycin in a study of 10 healthy volunteers who received single doses of dabigatran etexilate (300 mg) with or without clarithromycin (500 mg twice/day for 4 days).<sup>2</sup> In contrast, a study summarized dabigatran labeling reports that clarithromycin had only a minor impact on dabigatran concentrations (AUC and Cmax increased an average of 15% and 19%, respectively).<sup>3,4</sup><br><br>Dabigatran labeling notes that the prodrug (dabigatran etexilate) is a substrate with moderate affinity for the P-gp transport system, suggesting that the mechanism for these observed interactions is inhibition of P-gp resulting in increased dabigatran concentrations.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Delavenne X, Ollier E, Basset T, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. <i>Br J Clin Pharmacol</i>. 2013;76(1):107-113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23210726\">[PubMed 23210726]</a></p>\n<p>3. Pradaxa (dabigatran etexilate). [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; November 2016.</p>\n<p>4. Pradaxa (dabigatran etexilate). [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8210":"<p><b>Title</b> Barbiturates / Somatostatin Acetate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Somatostatin Acetate may enhance the adverse/toxic effect of Barbiturates. Specifically, Somatostatin Acetate may enhance or prolong Barbiturate effects, including sedative effects. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of barbiturates and somatostatin.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> Somatostatin summaries of product characteristics from some countries (e.g., Netherlands, Singapore) state that its use should be avoided in combination with hexobarbital and drugs exerting similar effects, because somatostatin prolongs hexobarbital induced sleep.<sup>1,2</sup> Published studies describing these effects in humans are not available, although some reports describe related effects in rodents treated with somatostatin in combination with barbiturates.<sup>3,4</sup> The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stilamin</i> (somatostatin acetate) [Singapore summary of product characteristics]. Aubonne, Switzerland: Merck Serono SA; November 2011.</p>\n<p>2. <i>Somatostatin-Eumedica</i> (somatostatin acetate) [Netherlands summary of product characteristics]. Brussels, Belgium: Eumedica NV; June 2012.</p>\n<p>3. Caprino L, Borrelli F, Antonetti F, Cantelmo A. Sex-related toxicity of somatostatin and its interaction with pentobarbital and strychnine. <i>Toxicol Lett</i>. 1983;17(1-2):145-149. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6137886\">[PubMed 6137886]</a></p>\n<p>4. Prange AJ Jr, Breese GR, Jahnke GD, et al. Modification of pentobarbital effects by natural and synthetic polypeptides: dissociation of brain and pituitary effects. <i>Life Sci</i>. 1975;16(12):1907-1913. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=239299\">[PubMed 239299]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8211":"<p><b>Title</b> Vitamin K Antagonists / Streptokinase</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Streptokinase may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid streptokinase in patients receiving (or who have recently received) any vitamin K antagonist and whose INR is above 1.3. Australian product labeling specifically lists this as a contraindication.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The streptokinase Australian summary of product characteristics lists its use in patients with an INR above 1.3 as contraindicated.<sup>1</sup> Bleeding risk is expected to be elevated in patients receiving streptokinase under these conditions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Streptase</i> (streptokinase) [Australia summary of product characteristics]. Parkville, Australia: CSL Limited; February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8212":"<p><b>Title</b> Heparin / Streptokinase</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Streptokinase may enhance the anticoagulant effect of Heparin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of heparin and streptokinase. Australian product labeling recommends administration of protamine to reverse heparin effects and verifying that thrombin time is twice control values or less before initiating streptokinase.</p> \n<p><b>Discussion</b> The streptokinase Australian summary of product characteristics states that protamine should be used to counteract anticoagulant effects of heparin, and thrombin time should be twice control values or less, prior to streptokinase administration.<sup>1</sup> Bleeding risk is expected to be elevated in patients receiving streptokinase in combination with heparin or other drugs that exert anticoagulant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Streptase</i> (streptokinase) [Australia summary of product characteristics]. Parkville, Australia: CSL Limited; February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8213":"<p><b>Title</b> Anticoagulants / Urokinase</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Continuation of heparin can be considered in patients receiving hemodialysis.</p></li>\n <li><p><b>Route</b>: This interaction is only expected when urokinase is administered systemically.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Urokinase may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid systemic urokinase in patients receiving (or who have recently received) anticoagulants. UK product labeling specifically lists this as a contraindication. In patients who have recently received heparin, verify that aPTT is twice control values or less before urokinase initiation. Continuation of heparin may be considered in patients receiving hemodialysis.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> UK summaries of product characteristics for urokinase list its use in patients with decreased blood coagulation as contraindicated.<sup>1,2</sup> Further, patients previously treated with heparin should generally have aPTT twice control values or less before urokinase initiation.<sup>1,2</sup> Bleeding risk is expected to be elevated in patients receiving urokinase in combination with any anticoagulant due to the independent anticoagulant effects of the drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Urokinase medac</i> (urokinase) [UK summary of product characteristics]. Hamburg, Germany: Medac Gesellschaft Fur Klinische Spezialpraparate; September 2010.</p>\n<p>2. <i>Syner-kinase</i> (urokinase) [UK summary of product characteristics]. Surrey, UK: Syner-Medica Ltd; May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8214":"<p><b>Title</b> Urokinase / Agents with Antiplatelet Properties</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only expected when urokinase is administered systemically.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of urokinase in combination with agents that exert antiplatelet effects.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> One UK summary of product characteristics for urokinase recommends avoiding its use in combination with agents that inhibit platelet function.<sup>1</sup> Bleeding risk is expected to be elevated in patients receiving urokinase in combination with any antiplatelet agent due to the independent effects of the agents on coagulation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Urokinase medac</i> (urokinase) [UK summary of product characteristics]. Hamburg, Germany: Medac Gesellschaft Fur Klinische Spezialpraparate; September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8215":"<p><b>Title</b> Rivaroxaban / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (P-glycoprotein Inhibitors (Clinically Relevant)): The significance of this interaction is expected to be greater in patients receiving P-glycoprotein inhibitors.</p></li>\n <li><p><b>International labeling</b>: Rivaroxaban US and Canadian product labels differ in their characterization of the significance of this interaction under some circumstances.</p></li>\n <li><p><b>Renal Function</b>: The significance of this interaction is expected to be greater in patients with renal impairment.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein. For erythromycin, refer to more specific erythromycin-rivaroxaban monograph recommendations. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action is typically needed when a moderate CYP3A4 inhibitor is administered with rivaroxaban. When combining rivaroxaban with a moderate CYP3A4 inhibitor in a patient also receiving a P-glycoprotein inhibitor, follow recommendations regarding use with combined CYP3A4 (moderate) and P-glycoprotein inhibitors, namely: per US labeling, no special caution is needed in patients with estimated creatinine clearance greater than 80 mL/min, but do not use rivaroxaban in patients with estimated creatinine clearance 15 to 80 mL/min unless the prospective benefits of treatment outweigh the risks; or per Canadian labeling, use rivaroxaban with caution in patients with estimated creatinine clearance 30 to 50 mL/min.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra<br><b>Exceptions</b> Dronedarone, Erythromycin (Systemic), Verapamil</p>\n</div> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with rivaroxaban (59.13% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, apixaban or dabigatran), use of the moderate CYP3A4 inhibitor fluconazole was associated with a 2.35-fold increase in the incidence rate ratio for major bleeding, equivalent to an additional 138.5 major bleeding episodes per 1000 person-years as compared to an anticoagulant user who did not receive fluconazole.<sup>1</sup> In contrast, concurrent use of the moderate CYP3A4 inhibitors diltiazem, dronedarone, or verapamil were not associated with a significant increase in the risk for major bleeding, and use of erythromycin or clarithromycin was associated with a 40% decrease in the incidence rate ratio for major bleeding. Several other examined combinations in this cohort study also yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>In a clinical study summarized in rivaroxaban labeling, concomitant use of the CYP3A4 moderate inhibitor and P-glycoprotein (P-gp) inhibitor erythromycin (500 mg 3 times daily) increased the rivaroxaban (10 mg daily) maximum serum concentration and AUC both by 1.3-fold.<sup>2,3</sup> Coadministration of erythromycin in subjects with renal impairment classified as mild (estimated creatinine clearance 50 to 79 mL/min) or moderate (estimated creatinine clearance 30 to 49 mL/min) increased the rivaroxaban AUC to approximately 1.8 and 2 times greater, respectively, than the AUC seen in subjects with normal renal function (estimated creatinine clearance &gt; 80 mL/min) not receiving erythromycin.<sup>2</sup> The rivaroxaban AUC was increased by an average of 42% with concurrent fluconazole in a study of 13 subjects who received a single dose of rivaroxaban 20 mg on day 5 of fluconazole (400 mg/day for 6 days).<sup>4</sup> Rivaroxaban clearance by active renal section was calculated to be 22% lower with fluconazole.<br><br>Rivaroxaban is a substrate of both CYP3A4 and P-gp, and its elimination is partially renally-dependent.<sup>2</sup> BCRP (ie, ABCG2) may also be at least partially involved in rivaroxaban disposition.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc.; March 2017.</p>\n<p>3. Xarelto (rivaroxaban) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; July 2015.</p>\n<p>4. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. <i>Br J Clin Pharmacol</i>. 2013;76(3):455-466. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23305158\">[PubMed 23305158]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8216":"<p><b>Title</b> Droxidopa / Serotonin 5-HT1D Receptor Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of droxidopa with drugs that increase blood pressure (such as the 5-HT1D receptor agonists) is expected to result in an increased risk for supine hypertension. Closely monitor patient blood pressure (including in supine and head-elevated positions) and for any evidence of toxicity. Follow other recommendations to manage this risk, such as having patients elevate the heads of their bed while sleeping or resting.</p>\n<div>\n <p><b>Serotonin 5-HT1D Receptor Agonists Interacting Members</b> Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, SUMAtriptan, ZOLMitriptan</p>\n</div> \n<p><b>Discussion</b> According to the prescribing information for droxidopa, its use is associated with a risk for supine hypertension, and it is expected that concurrent use of other drugs that can elevate the blood pressure would increase this risk.<sup>1</sup> During clinical trials droxidopa therapy (for 8-10 weeks) was associated with an increased incidence of hypertension compared to placebo (7% vs. 0.9%, respectively), but specific data regarding the incidence of supine hypertension are not provided.<sup>1</sup><br><br>The mechanism for this interaction is likely additive pressor effects of droxidopa, which is converted in vivo to norepinephrine, together with other drugs that can increase blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Northera</i> (droxidopa) [Prescribing information]. Charlotte, NC: Chelsea Therapeutics, Inc., February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8217":"<p><b>Title</b> Droxidopa / Norepinephrine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Norepinephrine may enhance the hypertensive effect of Droxidopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of droxidopa with drugs that increase blood pressure (such as norepinephrine) is expected to result in an increased risk for supine hypertension. Closely monitor patient blood pressure (including in supine and head-elevated positions) and for any evidence of toxicity. Follow other recommendations to manage this risk, such as having patients elevate the heads of their bed while sleeping or resting.</p> \n<p><b>Discussion</b> According to the prescribing information for droxidopa, its use is associated with a risk for supine hypertension, and it is expected that concurrent use of other drugs that can elevate the blood pressure would increase this risk.<sup>1</sup> During clinical trials droxidopa therapy (for 8-10 weeks) was associated with an increased incidence of hypertension compared to placebo (7% vs. 0.9%, respectively), but specific data regarding the incidence of supine hypertension are not provided.<sup>1</sup><br><br>The mechanism for this interaction is likely additive pressor effects of droxidopa, which is converted in vivo to norepinephrine, together with other drugs that can increase blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Northera</i> (droxidopa) [Prescribing information]. Charlotte, NC: Chelsea Therapeutics, Inc., February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8218":"<p><b>Title</b> Droxidopa / EPHEDrine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> EPHEDrine (Systemic) may enhance the hypertensive effect of Droxidopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of droxidopa with drugs that increase blood pressure (such as ephedrine) is expected to result in an increased risk for supine hypertension. Closely monitor patient blood pressure (including in supine and head-elevated positions) and for any evidence of toxicity. Follow other recommendations to manage this risk, such as having patients elevate the heads of their beds while sleeping or resting.</p> \n<p><b>Discussion</b> According to the prescribing information for droxidopa, its use is associated with a risk for supine hypertension, and it is expected that concurrent use of other drugs that can elevate blood pressure would increase this risk.<sup>1</sup> During clinical trials, droxidopa therapy (for 8-10 weeks) was associated with an increased incidence of hypertension compared to placebo (7% vs 0.9%), but specific data regarding the incidence of supine hypertension are not provided.<sup>1</sup><br><br>The mechanism for this interaction is likely additive pressor effects of droxidopa, which is converted in vivo to norepinephrine, together with other drugs that can increase blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Northera</i> (droxidopa) [prescribing information]. Charlotte, NC: Chelsea Therapeutics, Inc; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8219":"<p><b>Title</b> Droxidopa / Midodrine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Midodrine may enhance the hypertensive effect of Droxidopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of droxidopa with drugs that increase blood pressure (such as midodrine) is expected to result in an increased risk for supine hypertension. Closely monitor patient blood pressure (including in supine and head-elevated positions) and for any evidence of toxicity. Follow other recommendations to manage this risk, such as having patients elevate the heads of their bed while sleeping or resting.</p> \n<p><b>Discussion</b> According to the prescribing information for droxidopa, its use is associated with a risk for supine hypertension, and it is expected that concurrent use of other drugs that can elevate the blood pressure would increase this risk.<sup>1</sup> During clinical trials droxidopa therapy (for 8-10 weeks) was associated with an increased incidence of hypertension compared to placebo (7% vs. 0.9%, respectively), but specific data regarding the incidence of supine hypertension are not provided.<sup>1</sup><br><br>The mechanism for this interaction is likely additive pressor effects of droxidopa, which is converted in vivo to norepinephrine, together with other drugs that can increase blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Northera</i> (droxidopa) [Prescribing information]. Charlotte, NC: Chelsea Therapeutics, Inc., February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8220":"<p><b>Title</b> Droxidopa / Carbidopa</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbidopa may diminish the therapeutic effect of Droxidopa. Carbidopa may decrease serum concentrations of the active metabolite(s) of Droxidopa. Carbidopa may increase the serum concentration of Droxidopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of reduced response to droxidopa when used together with carbidopa.</p> \n<p><b>Discussion</b> Data regarding the magnitude and significance of this interaction are mixed. Small clinical studies (n=12-19) have showed that concurrent use of droxidopa with carbidopa was associated with a diminished pressor response to droxidopa,<sup>1,2</sup> while the droxidopa prescribing information states that patients receiving carbidopa did not require a different treatment dose or experience more adverse effects.<sup>3</sup> Though carbidopa does appear to increase average concentrations of droxidopa by approximately 2-fold,<sup>1,3</sup> the impact of this interaction on plasma norepinephrine concentrations is uncertain, with at least one study showing a blunting of plasma norepinephrine concentrations<sup>1</sup> and another showing no difference.<sup>2</sup><br><br>The mechanism for this interaction is carbidopa inhibition of the dopa-decarboxylase-mediated conversion of droxidopa into its active metabolite, norepinephrine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. <i>Circulation</i>. 2003 Aug 12;108(6):724-728. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12885750\">[PubMed 12885750]</a></p>\n<p>2. Goldstein DS, Holmes C, Sewell L, Pechnik S, Kopin IJ. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. <i>J Clin Pharmacol</i>. 2011;51(1):66-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20220040\">[PubMed 20220040]</a></p>\n<p>3. <i>Northera</i> (droxidopa) [Prescribing information]. Charlotte, NC: Chelsea Therapeutics, Inc., February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8221":"<p><b>Title</b> Amphetamine / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may increase the absorption of Amphetamine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for the signs/symptoms of excessive amphetamine response, particularly in the first few hours after administration.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The rate of absorption for both <i>d</i>- and <i>l</i>-amphetamine from an extended release formulation of mixed amphetamine salts was significantly increased with concurrent omeprazole in a study of 24 healthy volunteers.<sup>1,2</sup> The time to maximum plasma concentration was decreased from 4 to 2.8 hours for <i>d</i>-amphetamine and from 5 to 2.75 hours for <i>l</i>-amphetamine when mixed amphetamine salts (20 mg x1) were given to volunteers treated with omeprazole (40 mg/day x 14 days). Overall amphetamine exposure was not significantly affected.<sup>1,2</sup> Although this interaction has only been demonstrated for the extended release mixed amphetamine salts product, the prescribing information for another amphetamine product also cautions that gastrointestinal alkalinizing agents may increase amphetamine absorption.<sup>3</sup><br><br>It is suspected that amphetamine absorption increases in a more alkaline gastrointestinal environment, leading to increased systemic amphetamine concentrations.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adderall XR</i> (extended release mixed amphetamine salts) [prescribing information]. Wayne, PA: Shire US Inc.; November 2010.</p>\n<p>2. Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. <i>Postgrad Med</i>. 2009;121(5):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19820270\">[PubMed 19820270]</a></p>\n<p>3. <i>Evekeo</i> (amphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8222":"<p><b>Title</b> Dextroamphetamine / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b> (Capsule, extended release): This interaction has only been described with mixed amphetamine salt extended release (XR) capsules.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for the signs/symptoms of excessive amphetamine response, particularly in the few hours after administration.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The rate of absorption for both <i>d</i>- and <i>l</i>-amphetamine from an extended release formulation of mixed amphetamine salts was significantly increased with concurrent omeprazole in a study of 24 healthy volunteers.<sup>1,2</sup> The time to maximum plasma concentration was decreased from 4 to 2.8 hours for <i>d</i>-amphetamine and from 5 to 2.75 hours for <i>l</i>-amphetamine when mixed amphetamine salts (20 mg x1) were given to volunteers treated with omeprazole (40 mg/day x 14 days). Overall amphetamine exposure was not significantly affected.<sup>1,2</sup><br><br>The suspected primary mechanism of this interaction is an increase in amphetamine release rate from the extended release formulation due to increased gastric pH.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adderall XR</i> (extended release mixed amphetamine salts) [prescribing information]. Wayne, PA: Shire US Inc.; November 2010.</p>\n<p>2. Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. <i>Postgrad Med</i>. 2009;121(5):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19820270\">[PubMed 19820270]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8223":"<p><b>Title</b> Insulins / Metreleptin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Metreleptin may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin. Monitor blood glucose and all signs/symptoms of hypoglycemia closely following the initiation of metreleptin. The risk may be greatest for patients receiving higher insulin doses.</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> A total of 7 episodes of hypoglycemia involving 6 (13%) patients receiving metreleptin were reported in a clinical trial summarized in the metreleptin prescribing information.<sup>1</sup> Of these, 6 of the 7 episodes involved concurrent use of insulin. The prescribing information specifically cautions that potentially large dosage reductions may be needed for patients receiving insulin and/or an insulin secretagogue (e.g., sulfonylurea).<sup>1</sup><br><br>The specific mechanism for this potential interaction is not certain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myalept</i> (metreleptin) [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8224":"<p><b>Title</b> Sulfonylureas / Metreleptin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Metreleptin may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin. Monitor blood glucose and all signs/symptoms of hypoglycemia closely following the initiation of metreleptin.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> A total of 7 episodes of hypoglycemia involving 6 (13%) patients receiving metreleptin were reported in a clinical trial summarized in the metreleptin prescribing information.<sup>1</sup> Of these, 6 of the 7 episodes involved concurrent use of insulin. The prescribing information specifically cautions that potentially large dosage reductions may be needed for patients receiving insulin and/or an insulin secretagogue (e.g., sulfonylurea).<sup>1</sup><br><br>The specific mechanism for this potential interaction is not certain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myalept</i> (metreleptin) [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8225":"<p><b>Title</b> Warfarin / Metreleptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metreleptin may decrease the serum concentration of Warfarin. Metreleptin may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to warfarin (i.e., INR, evidence of bleeding or bruising, etc.) more closely when starting or stopping metreleptin. Patients may experience either an increase or decrease in warfarin response.</p> \n<p><b>Discussion</b> The metreleptin prescribing information cautions that leptin may alter the expression of drug metabolizing enzymes and that, as a result, concentrations and/or effects of narrow therapeutic index drugs, such as warfarin, may be altered when starting or stopping therapy with a leptin analog like metreleptin.<sup>1</sup> Some animal data do suggest both a possible change in some drug metabolizing enzymes with altered leptin signaling and possible changes in drug metabolizing enzymes with leptin administration (to both lean and obese animals), but these effects vary substantially among enzymes and according to treatment group (e.g., lean vs. obese, leptin treatment, etc.).<sup>2</sup> In addition, the effect of leptin administration on drug administration in humans, with or without altered leptin signaling at baseline, is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myalept</i> (metreleptin) [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, February 2014.</p>\n<p>2. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. <i>Drug Metab Dispos</i>. 1999;27(6):695-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348799\">[PubMed 10348799]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8226":"<p><b>Title</b> CycloSPORINE (Systemic) / Metreleptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metreleptin may decrease the serum concentration of CycloSPORINE (Systemic). Metreleptin may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to cyclosporine (i.e., cyclosporine serum concentrations, evidence of toxicity, etc.) more closely when starting or stopping metreleptin. Patients may experience either an increase or decrease in cyclosporine response.</p> \n<p><b>Discussion</b> The metreleptin prescribing information cautions that leptin may alter the expression of drug metabolizing enzymes and that, as a result, concentrations and/or effects of narrow therapeutic index drugs, such as cyclosporine, may be altered when starting or stopping therapy with a leptin analog like metreleptin.<sup>1</sup> Some animal data do suggest both a possible change in some drug metabolizing enzymes with altered leptin signaling and possible changes in drug metabolizing enzymes with leptin administration (to both lean and obese animals), but these effects vary substantially among enzymes and according to treatment group (e.g., lean vs. obese, leptin treatment, etc.).<sup>2</sup> In addition, the effect of leptin administration on drug administration in humans, with or without altered leptin signaling at baseline, is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myalept</i> (metreleptin) [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, February 2014.</p>\n<p>2. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. <i>Drug Metab Dispos</i>. 1999;27(6):695-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348799\">[PubMed 10348799]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8227":"<p><b>Title</b> Theophylline / Metreleptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metreleptin may decrease the serum concentration of Theophylline. Metreleptin may increase the serum concentration of Theophylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to theophylline (i.e., theophylline serum concentrations, evidence of toxicity, etc.) more closely when starting or stopping metreleptin. Patients may experience either an increase or decrease in theophylline response.</p> \n<p><b>Discussion</b> The metreleptin prescribing information cautions that leptin may alter the expression of drug metabolizing enzymes and that, as a result, concentrations and/or effects of narrow therapeutic index drugs, such as theophylline, may be altered when starting or stopping therapy with a leptin analog like metreleptin.<sup>1</sup> Some animal data do suggest both a possible change in some drug metabolizing enzymes with altered leptin signaling and possible changes in drug metabolizing enzymes with leptin administration (to both lean and obese animals), but these effects vary substantially among enzymes and according to treatment group (e.g., lean vs. obese, leptin treatment, etc.).<sup>2</sup> In addition, the effect of leptin administration on drug administration in humans, with or without altered leptin signaling at baseline, is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myalept</i> (metreleptin) [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, February 2014.</p>\n<p>2. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. <i>Drug Metab Dispos</i>. 1999;27(6):695-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348799\">[PubMed 10348799]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8228":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Metreleptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metreleptin may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Metreleptin may increase the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that leptin analogs may alter the metabolism of estrogens and other sex steroids, possibly altering the clinical effectiveness of such agents. The magnitude and clinical significance of any such effect is unknown. Discuss this possibility with patients along with whether or not an alternative means of contraceptive should be used.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> The metreleptin prescribing information cautions that leptin may alter the expression of drug metabolizing enzymes and that, as a result, concentrations and/or effects of hormone-based contraceptives and narrow therapeutic index drugs, may be altered when starting or stopping therapy with a leptin analog like metreleptin.<sup>1</sup> Some animal data do suggest both a possible change in some drug metabolizing enzymes with altered leptin signaling and possible changes in drug metabolizing enzymes with leptin administration (to both lean and obese animals), but these effects vary substantially among enzymes and according to treatment group (e.g., lean vs. obese, leptin treatment, etc.).<sup>2</sup> In addition, leptin has been shown in vitro to alter the production and metabolism of sex steroids in adipocytes.<sup>3</sup> Of importance, however, the clinical significance of these data from animal and in vitro studies is uncertain, as the effects of leptin administration on drug action in humans, with or without altered leptin signaling at baseline, is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myalept</i> (metreleptin) [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, February 2014.</p>\n<p>2. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. <i>Drug Metab Dispos</i>. 1999;27(6):695-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348799\">[PubMed 10348799]</a></p>\n<p>3. Dieudonne MN, Sammari A, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Sex steroids and leptin regulate 11beta-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: Sex specificities. <i>J Steroid Biochem Mol Biol</i>. 2006;99(4-5):189-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16621515\">[PubMed 16621515]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8229":"<p><b>Title</b> Progestins (Contraceptive) / Metreleptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metreleptin may decrease the serum concentration of Progestins (Contraceptive). Metreleptin may increase the serum concentration of Progestins (Contraceptive). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that leptin analogs may alter the metabolism of progestins and other sex steroids, possibly altering the clinical effectiveness of such agents. The magnitude and clinical significance of any such effect is unknown. Discuss this possibility with patients along with whether or not an alternative means of contraceptive should be used.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The metreleptin prescribing information cautions that leptin may alter the expression of drug metabolizing enzymes and that, as a result, concentrations and/or effects of hormone-based contraceptives and narrow therapeutic index drugs, may be altered when starting or stopping therapy with a leptin analog like metreleptin.<sup>1</sup> Some animal data do suggest both a possible change in some drug metabolizing enzymes with altered leptin signaling and possible changes in drug metabolizing enzymes with leptin administration (to both lean and obese animals), but these effects vary substantially among enzymes and according to treatment group (e.g., lean vs. obese, leptin treatment, etc.).<sup>2</sup> In addition, leptin has been shown in vitro to alter the production and metabolism of sex steroids in adipocytes.<sup>3</sup> Of importance, however, the clinical significance of these data from animal and in vitro studies is uncertain, as the effects of leptin administration on drug action in humans, with or without altered leptin signaling at baseline, is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myalept</i> (metreleptin) [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, February 2014.</p>\n<p>2. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. <i>Drug Metab Dispos</i>. 1999;27(6):695-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348799\">[PubMed 10348799]</a></p>\n<p>3. Dieudonne MN, Sammari A, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Sex steroids and leptin regulate 11beta-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: Sex specificities. <i>J Steroid Biochem Mol Biol</i>. 2006;99(4-5):189-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16621515\">[PubMed 16621515]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8257":"<p><b>Title</b> Doxazosin / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Doxazosin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of doxazosin and boceprevir. Boceprevir U.S. prescribing information specifically lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Boceprevir U.S. prescribing information lists its combination with doxazosin as contraindicated, due to a potential for boceprevir to potentiate doxazosin alpha 1 blockade.<sup>1</sup> The suspected primary mechanism of this interaction is boceprevir inhibition of CYP3A mediated doxazosin metabolism, resulting in increased doxazosin exposure. A published case report describes a doxazosin treated patient who developed priapism requiring shunt placement shortly after initiation of boceprevir, although the relation of this specifically to a doxazosin-boceprevir interaction is unclear due to several factors (chiefly the concomitant use of other potentially interacting drugs including tamsulosin and quetiapine).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Victrelis</i> (boceprevir) [prescribing information]. W hitehouse Station, NJ: Merck &amp; Co., Inc.; February 2014.</p>\n<p>2. Hammond KP, Nielsen C, Linnebur SA, et al. Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. <i>Clin Infect Dis</i>. 2014;58(1):e35-e38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24092799\">[PubMed 24092799]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8258":"<p><b>Title</b> Terbinafine (Systemic) / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Terbinafine (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study summarized in terbinafine U.S. prescribing information, coadministration of fluconazole (100 mg single dose) increased the maximum concentration and AUC of a single dose of terbinafine by 52% and 69%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is fluconazole inhibition of terbinafine metabolism (e.g., via CYP2C9 and/or 3A4).</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lamisil</i> (terbinafine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8259":"<p><b>Title</b> Disopyramide / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Disopyramide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of disopyramide and systemic ketoconazole. Ketoconazole U.S. prescribing information specifically lists this as a contraindication.</p> \n<p><b>Discussion</b> Ketoconazole U.S. prescribing information lists its combination with disopyramide as contraindicated due to the potential for increased disopyramide exposure and excessive QTc interval prolongation.<sup>1</sup> Ketoconazole is expected to increase disopyramide exposure primarily via inhibition of its CYP3A-mediated metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Nizoral</i> (ketoconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2014.</p>\n<p>2. Zhang L, Fitzloff JF, Engel LC, Cook CS. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. <i>Xenobiotica</i>. 2001;31(2):73-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11407536\">[PubMed 11407536]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8260":"<p><b>Title</b> Felodipine / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Felodipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ketoconazole and felodipine. This combination is listed as contraindicated in ketoconazole U.S. prescribing information.</p> \n<p><b>Discussion</b> Ketoconazole U.S. prescribing information lists its use in combination with felodipine as contraindicated.<sup>1</sup> No clinical data specifically characterizing the potential magnitude of interaction between these agents are available. In a clinical study of 9 healthy volunteers, coadministration of the closely related antifungal agent itraconazole (200 mg orally daily for 4 days) increased the maximum concentration and AUC of felodipine (5 mg single oral dose) by roughly 8 and 6 fold, respectively.<sup>2</sup> Itraconazole coadministration was associated with enhanced blood pressure lowering and heart rate elevating effects of felodipine.<sup>2</sup> Two additional published case reports describe patients who developed edema and swelling in the legs shortly after initiating this combination.<sup>3</sup><br><br>The suspected primary mechanism of this interaction is itraconazole inhibition of CYP3A mediated felodipine metabolism. Consequently, a similar interaction may be expected with ketoconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Nizoral</i> (ketoconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2014.</p>\n<p>2. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. <i>Clin Pharmacol Ther</i>. 1997;61(4):410-415. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9129558\">[PubMed 9129558]</a></p>\n<p>3. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. <i>J Am Acad Dermatol</i>. 1995;33(1):134-135. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7601933\">[PubMed 7601933]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8261":"<p><b>Title</b> Ketoconazole (Systemic) / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the concomitant use of efavirenz and systemic ketoconazole. Ketoconazole U.S. prescribing information specifically lists this as a contraindication.</p> \n<p><b>Discussion</b> In a clinical study of 12 HIV-infected patients, coadministration of efavirenz (600 mg daily) in combination with lamivudine (150 mg twice daily) and stavudine (30-40 mg twice daily) decreased the ketoconazole (400 mg single oral dose) maximum plasma concentration and AUC by 44% and 73%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is efavirenz induction of ketoconazole metabolism (e.g., via CYP3A). Ketoconazole U.S. prescribing information specifically lists its combination with efavirenz as contraindicated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, Jaruratanasirikul S. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. <i>Eur J Clin Pharmacol</i>. 2007;63(5):479-483. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17345073\">[PubMed 17345073]</a></p>\n<p>2. <i>Nizoral</i> (ketoconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8263":"<p><b>Title</b> Cannabis / CYP2C9 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is only expected when physiologically significant amounts of tetrahydrocannabinol (THC, the major known psychoactive component of cannabis) are introduced systemically. While this encompasses the vast majority of medical and recreational cannabis use, some cannabis strains, products, and routes of administration specifically (and often intentionally) minimize systemic THC exposure.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use cannabis in combination with moderate CYP2C9 inhibitors closely for enhanced effects of tetrahydrocannabinol (THC; e.g., cognitive effects, sedation, dizziness, tachycardia). No significant interaction has been described, or is expected, between moderate CYP2C9 inhibitors and cannabis strains/products/uses that do not introduce substantial systemic THC concentrations.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 43 nonsmoking healthy volunteers, plasma tetrahydrocannabinol AUC following a single 15 mg dose of (-)-delta-THC was 2-3 fold greater in patients with <i>CYP2C9</i> genotypes associated with reduced CYP2C9 enzyme function.<sup>1</sup> Exposure to the active hydroxylated metabolite of THC was unchanged, while exposure to the main carboxylated metabolite were significantly lower in subjects with lower expected CYP2C9 function. THC-associated sedation tended to be higher in a small sample of subjects with the lowest expected CYP2C9 function based on <i>*3/*3</i> genotype.<br><br>Several in vitro studies have identified CYP2C9 as capable of catalyzing THC metabolism.<sup>2,3,4,5</sup> While the impact of coadministration of specific CYP2C9 inhibitors on oral THC exposure has not been investigated, exposure increases of 2-3 fold may occur based on the above data. Systemic exposure to THC administered via other routes (e.g., oromucosal, inhaled) is also expected to increase with coadministration of a CYP2C9 inhibitor. Cannabinol (another cannabinoid commonly found in cannabis and cannabis products) may also be metabolized by CYP2C9, although the significance of this to the clinical effects of cannabis has not been investigated.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. <i>Clin Pharmacol Ther</i>. 2009;85(3):273-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19005461\">[PubMed 19005461]</a></p>\n<p>2. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. <i>Biol Pharm Bull</i>. 1995;18(8):1138-1141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8535411\">[PubMed 8535411]</a></p>\n<p>3. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p>4. Richardson TH, Jung F, Griffin KJ, et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. <i>Arch Biochem Biophys</i>. 1995;323(1):87-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7487078\">[PubMed 7487078]</a></p>\n<p>5. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. <i>Biochem Pharmacol</i>. 2005;70(7):1096-1103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16112652\">[PubMed 16112652]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8264":"<p><b>Title</b> Cannabis / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is mainly expected when physiologically significant amounts of tetrahydrocannabinol (THC, the major known psychoactive component of cannabis) are introduced systemically. While this encompasses the vast majority of medical and recreational cannabis use, some cannabis strains, products, and routes of administration specifically (and often intentionally) minimize systemic THC exposure. While cannabidiol concentrations are also likely increased by CYP3A4 inhibition, the clinical significance of this increase is less clear.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use cannabis in combination with strong CYP3A4 inhibitors closely for enhanced effects of tetrahydrocannabinol (THC; e.g., cognitive effects, sedation, dizziness, tachycardia) and cannabidiol (CBD; e.g., muscle relaxant effects). No significant interaction has been described, or is expected, between strong CYP3A4 inhibitors and cannabis strains/products/uses that do not introduce substantial systemic THC or CBD concentrations.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the U.K. summary of product characteristics for tetrahydrocannabinol (THC) and cannabidiol (CBD) oromucosal spray, coadministration of ketoconazole increased the maximum concentration (Cmax) and AUC of THC by 1.2 and 1.8 fold, respectively, while the Cmax and AUC of its primary hydroxylated metabolite increased by 3 and 3.6 fold, respectively.<sup>1</sup> The Cmax and AUC of CBD both increased by 2 fold.<br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated metabolism of THC and CBD. Systemic exposure to these cannabinoids administered via other routes (e.g., oral, inhaled) is also expected to increase with coadministration of a CYP3A4 inhibitor. Cannabinol (another cannabinoid commonly found in cannabis and cannabis products) may also be metabolized by CYP3A4, although the significance of this to the clinical effects of cannabis has not been investigated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [UK summary of product characteristics]. Wiltshire, UK: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8265":"<p><b>Title</b> Cannabis / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is mainly expected when physiologically significant amounts of tetrahydrocannabinol (THC, the major known psychoactive component of cannabis) are introduced systemically. While this encompasses the vast majority of medical and recreational cannabis use, some cannabis strains, products, and routes of administration specifically (and often intentionally) minimize systemic THC exposure. While cannabidiol concentrations are also likely increased by CYP3A4 inhibition, the clinical significance of this increase is less clear.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use cannabis in combination with moderate CYP3A4 inhibitors closely for enhanced effects of tetrahydrocannabinol (THC; e.g., cognitive effects, sedation, dizziness, tachycardia) and cannabidiol (CBD; e.g., muscle relaxant effects). No significant interaction has been described, or is expected, between moderate CYP3A4 inhibitors and cannabis strains/products/uses that do not introduce substantial systemic THC or CBD concentrations.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the U.K. summary of product characteristics for tetrahydrocannabinol (THC) and cannabidiol (CBD) oromucosal spray, coadministration of ketoconazole increased the maximum concentration (Cmax) and AUC of THC by 1.2 and 1.8 fold, respectively, while the Cmax and AUC of its primary hydroxylated metabolite increased by 3 and 3.6 fold, respectively.<sup>1</sup> The Cmax and AUC of CBD both increased by 2 fold.<br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated metabolism of THC and CBD. Systemic exposure to these cannabinoids administered via other routes (e.g., oral, inhaled) is also expected to increase with coadministration of a CYP3A4 inhibitor. Cannabinol (another cannabinoid commonly found in cannabis and cannabis products) may also be metabolized by CYP3A4, although the significance of this to the clinical effects of cannabis has not been investigated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [UK summary of product characteristics]. Wiltshire, UK: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8266":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inducers) / Cannabis</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction has only been described with smoked cannabis herb (i.e., marijuana).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cannabis may decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for reduced serum concentrations (when available) and effects of CYP1A2 substrates in patients who smoke cannabis or increase cannabis smoking. Similarly, monitor for increased serum concentrations and effects of CYP1A2 substrates in patients who stop or reduce smoking cannabis. It is not presently clear whether non-marijuana cannabis products (e.g., hash) carry a risk similar to marijuana.</p>\n<div>\n <p><b>CYP1A2 Substrates (High risk with Inducers) Interacting Members</b> Acebrophylline, Acenocoumarol, Aminophylline, Asenapine, ClomiPRAMINE, Dacarbazine, DULoxetine, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estropipate, Flutamide, FluvoxaMINE, Lidocaine (Systemic), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Propranolol, Ramosetron, Rasagiline, ROPINIRole, Stiripentol, Tasimelteon, Theophylline, Thiothixene, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> Three published clinical studies describe increased rates of systemic theophylline clearance in individuals who reported smoking marijuana.<sup>1,2,3</sup> In one of these reports, theophylline clearance in individuals who reported smoking 2 joints or more per week was 48% greater than in individuals reporting no marijuana use, while individuals who reported smoking less than 1 joint per week had similar theophylline clearance rates to those reporting no use.<sup>1</sup> In another study, estimated theophylline clearance was 42% greater in individuals who reported smoking marijuana and 79% greater in individuals who reported smoking both marijuana and tobacco compared to nonsmokers.<sup>2</sup> Similarly, chlorpromazine clearance in schizophrenic patients in one report was 50% greater in marijuana smokers and 107% greater in combined marijuana and tobacco smokers as compared to nonsmoking patients.<sup>4</sup><br><br>In addition to the above studies, one case report describes a 37 year old schizophrenic man who had increases in clozapine plasma concentrations and worsening of symptoms (agitation, acoustic hallucinations, and paranoia) in the 3 months following marijuana smoking cessation.<sup>5</sup> The clozapine dose was reduced, and both the plasma clozapine concentration and the symptoms returned to their pre-marijuana cessation state within 1 week.<br><br>The suspected primary mechanism of the above interactions is induction of CYP1A2 mediated metabolism of theophylline, chlorpromazine, and possibly clozapine caused by smoking marijuana.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. <i>J Pharm Sci</i>. 1979;68(11):1358-1366. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=41932\">[PubMed 41932]</a></p>\n<p>2. Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM. Enhanced biotransformation of theophylline in marihuana and tobacco smokers. <i>Clin Pharmacol Ther</i>. 1978;24(4):405-410. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688731\">[PubMed 688731]</a></p>\n<p>3. Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R. Effects of tobacco smoking and oral contraceptive use on theophylline disposition. <i>Br J Clin Pharmacol</i>. 1983;16(3):271-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6626419\">[PubMed 6626419]</a></p>\n<p>4. Chetty M, Miller R, Moodley SV. Smoking and body weight influence the clearance of chlorpromazine. <i>Eur J Clin Pharmacol</i>. 1994;46(6):523-526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7995319\">[PubMed 7995319]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8267":"<p><b>Title</b> Cannabis / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is mainly expected to reduce systemic concentrations and effects of tetrahydrocannabinol and cannabidiol. Patients using a cannabis strain, product, or route of administration that does not introduce physiologically significant amounts of these compounds may not be affected.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use cannabis in combination with strong CYP3A4 inducers closely for reduced systemic effects of tetrahydrocannabinol (THC) and cannabidiol (CBD). No significant interaction has been described between strong CYP3A4 inducers and cannabis strains/products/uses that do not introduce substantial systemic THC or CBD concentrations.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the U.K. summary of product characteristics for tetrahydrocannabinol (THC) and cannabidiol (CBD) oromucosal spray, coadministration of rifampin decreased the maximum concentration (Cmax) and AUC of THC by 40% and 20%, respectively, while the Cmax and AUC of its primary hydroxylated metabolite were reduced by 85% and 87%, respectively.<sup>1</sup> The Cmax and AUC of CBD decreased by 50% and 60%, respectively.<br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated metabolism of THC and CBD. Rifampin induction of other pathways, particularly CYP2C9 for THC, also likely contributes. Systemic exposure to THC and CBD administered via other routes (e.g., oral, inhaled) is also expected to increase with coadministration of a CYP3A4 inducer. Cannabinol (another cannabinoid commonly found in cannabis and cannabis products) may also be metabolized by CYP3A4, although the significance of this to the clinical effects of cannabis has not been investigated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [U.K. summary of product characteristics]. Wiltshire, U.K.: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8268":"<p><b>Title</b> Tetrahydrocannabinol / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use tetrahydrocannabinol (THC) in combination with moderate CYP2C9 inhibitors closely for enhanced THC effects (e.g., cognitive effects, sedation, dizziness, tachycardia).</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 43 nonsmoking healthy volunteers, plasma tetrahydrocannabinol AUC following a single 15 mg dose of (-)-delta-THC was 2-3 fold greater in patients with <i>CYP2C9</i> genotypes associated with reduced CYP2C9 enzyme function.<sup>1</sup> Exposure to the active hydroxylated metabolite of THC was unchanged, while exposure to the main carboxylated metabolite was significantly lower in subjects with lower expected CYP2C9 function. THC-associated sedation tended to be higher in a small sample of subjects with the lowest expected CYP2C9 function based on <i>*3/*3</i> genotype.<br><br>Several in vitro studies have identified CYP2C9 as capable of catalyzing THC metabolism.<sup>2,3,4,5</sup> While the impact of coadministration of specific CYP2C9 inhibitors on oral THC exposure has not been investigated, exposure increases of 2-3 fold may occur based on the above data.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. <i>Clin Pharmacol Ther</i>. 2009;85(3):273-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19005461\">[PubMed 19005461]</a></p>\n<p>2. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. <i>Biol Pharm Bull</i>. 1995;18(8):1138-1141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8535411\">[PubMed 8535411]</a></p>\n<p>3. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p>4. Richardson TH, Jung F, Griffin KJ, et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in <i>Escherichia coli</i>. <i>Arch Biochem Biophys</i>. 1995;323(1):87-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7487078\">[PubMed 7487078]</a></p>\n<p>5. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. <i>Biochem Pharmacol</i>. 2005;70(7):1096-1103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16112652\">[PubMed 16112652]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8270":"<p><b>Title</b> Tetrahydrocannabinol / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use tetrahydrocannabinol (THC) in combination with moderate CYP3A4 inhibitors closely for enhanced effects of THC (e.g., cognitive effects, sedation, dizziness, tachycardia).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 5 days) and 4 sprays of the tetrahydrocannabinol (THC) and cannabidiol oromucosal spray increased the maximum concentration (Cmax) and AUC of THC by 1.3-fold and 1.8 fold, respectively, while the Cmax and AUC of its primary hydroxylated metabolite increased by 3.0-fold and 3.5-fold, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated metabolism of THC.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stott C, White L, Wright S, Wilbraham D, Guy G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. <i>Springerplus</i>. 2013;2(1):236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23750331\">[PubMed 23750331]</a></p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8271":"<p><b>Title</b> Tetrahydrocannabinol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients who use tetrahydrocannabinol (THC) in combination with strong CYP3A4 inhibitors closely for enhanced effects of THC (e.g., cognitive effects, sedation, dizziness, tachycardia).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of ketoconazole (400 mg daily x 5 days) and 4 sprays of the tetrahydrocannabinol (THC) and cannabidiol oromucosal spray increased the maximum concentration (Cmax) and AUC of THC by 1.3-fold and 1.8 fold, respectively, while the Cmax and AUC of its primary hydroxylated metabolite increased by 3.0-fold and 3.5-fold, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated metabolism of THC.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stott C, White L, Wright S, Wilbraham D, Guy G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. <i>Springerplus</i>. 2013;2(1):236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23750331\">[PubMed 23750331]</a></p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8272":"<p><b>Title</b> Tetrahydrocannabinol / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: UK product labeling for tetrahydrocannabinol/cannabidiol oromucosal spray recommends avoiding use of this product in combination with strong CYP3A4 inducers. Labeling in other areas may differ (eg, Canadian labeling gives no specific management recommendation).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients who use tetrahydrocannabinol (THC) in combination with strong CYP3A4 inducers closely for reduced systemic effects of THC.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of rifampin (600 mg daily x 10 days) and 4 sprays of the tetrahydrocannabinol (THC) and cannabidiol oromucosal spray, decreased the maximum concentration (Cmax) and AUC of THC by 36% and 24%, respectively, while the Cmax and AUC of its primary hydroxylated metabolite were both reduced by 87%.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated metabolism of THC. Rifampin induction of other pathways, particularly CYP2C9, also likely contributes.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stott C, White L, Wright S, Wilbraham D, Guy G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. <i>Springerplus</i>. 2013;2(1):236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23750331\">[PubMed 23750331]</a></p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8273":"<p><b>Title</b> Dronabinol / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use dronabinol in combination with moderate CYP2C9 inhibitors closely for enhanced dronabinol effects (e.g., cognitive effects, sedation, dizziness, tachycardia).</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 43 nonsmoking healthy volunteers, plasma tetrahydrocannabinol AUC following a single 15 mg dose of (-)-delta-THC was 2-3 fold greater in patients with <i>CYP2C9</i> genotypes associated with reduced CYP2C9 enzyme function.<sup>1</sup> Exposure to the active hydroxylated metabolite of THC was unchanged, while exposure to the main carboxylated metabolite was significantly lower in subjects with lower expected CYP2C9 function. THC-associated sedation tended to be higher in a small sample of subjects with the lowest expected CYP2C9 function based on <i>*3/*3</i> genotype.<br><br>Several in vitro studies have identified CYP2C9 as capable of catalyzing THC metabolism.<sup>2,3,4,5</sup> While the impact of coadministration of specific CYP2C9 inhibitors on oral THC exposure has not been investigated, exposure increases of 2-3 fold may occur based on the above data.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. <i>Clin Pharmacol Ther</i>. 2009;85(3):273-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19005461\">[PubMed 19005461]</a></p>\n<p>2. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. <i>Biol Pharm Bull</i>. 1995;18(8):1138-1141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8535411\">[PubMed 8535411]</a></p>\n<p>3. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p>4. Richardson TH, Jung F, Griffin KJ, et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in <i>Escherichia coli</i>. <i>Arch Biochem Biophys</i>. 1995;323(1):87-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7487078\">[PubMed 7487078]</a></p>\n<p>5. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. <i>Biochem Pharmacol</i>. 2005;70(7):1096-1103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16112652\">[PubMed 16112652]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8275":"<p><b>Title</b> Dronabinol / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients who use dronabinol in combination with moderate CYP3A4 inhibitors closely for enhanced effects of dronabinol (e.g., cognitive effects, sedation, dizziness, tachycardia).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the U.K. summary of product characteristics for tetrahydrocannabinol (THC) and cannabidiol oromucosal spray, coadministration of ketoconazole increased the maximum concentration (Cmax) and AUC of THC by 1.2 and 1.8 fold, respectively, while the Cmax and AUC of its primary hydroxylated metabolite increased by 3 and 3.6 fold, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated metabolism of THC</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [UK summary of product characteristics]. Wiltshire, UK: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8276":"<p><b>Title</b> Dronabinol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients who use dronabinol in combination with strong CYP3A4 inhibitors closely for enhanced effects of dronabinol (e.g., cognitive effects, sedation, dizziness, tachycardia).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the U.K. summary of product characteristics for tetrahydrocannabinol (THC) and cannabidiol oromucosal spray, coadministration of ketoconazole increased the maximum concentration (Cmax) and AUC of THC by 1.2 and 1.8 fold, respectively, while the Cmax and AUC of its primary hydroxylated metabolite increased by 3 and 3.6 fold, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated metabolism of THC</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [UK summary of product characteristics]. Wiltshire, UK: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8277":"<p><b>Title</b> Dronabinol / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients who use dronabinol in combination with strong CYP3A4 inducers closely for reduced systemic effects of dronabinol.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the U.K. summary of product characteristics for tetrahydrocannabinol (THC) and cannabidiol oromucosal spray, coadministration of rifampin decreased the maximum concentration (Cmax) and AUC of THC by 40% and 20%, respectively, while the Cmax and AUC of its primary hydroxylated metabolite were reduced by 85% and 87%, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated metabolism of THC. Rifampin induction of other pathways, particularly CYP2C9, also likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [UK summary of product characteristics]. Wiltshire, UK: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8278":"<p><b>Title</b> Cannabidiol / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: UK product labeling for tetrahydrocannabinol/cannabidiol oromucosal spray recommends avoiding use of this product in combination with strong CYP3A4 inducers. Labeling in other areas may differ (eg, Canadian labeling gives no specific management recommendation).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabidiol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients who use cannabidiol (CBD) in combination with strong CYP3A4 inducers closely for reduced systemic CBD effects.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of rifampin (600 mg daily x 10 days) and 4 sprays of the tetrahydrocannabinol and cannabidiol (CBD) oromucosal spray decreased the maximum concentration (Cmax) and AUC of CBD by 51% and 58%, respectively.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated metabolism of CBD.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Stott C, White L, Wright S, Wilbraham D, Guy G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. <i>Springerplus</i>. 2013;2(1):236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23750331\">[PubMed 23750331]</a></p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8279":"<p><b>Title</b> CNS Depressants / Cannabis</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is only expected when physiologically significant amounts of tetrahydrocannabinol (THC, the major known psychoactive component of cannabis) are introduced systemically. While this encompasses the vast majority of medical and recreational cannabis use, some cannabis strains, products, and routes of administration specifically (and often intentionally) minimize systemic THC exposure.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cannabis may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use cannabis concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants. These effects are likely largely or exclusively due to tetrahydrocannabinol (THC), and thus are not anticipated with the use of cannabis strains/products/uses that do not introduce substantial systemic THC concentrations.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Numerous published studies indicate that acute use of cannabis or tetrahydrocannabinol (THC, the primary known psychoactive component of cannabis) can enhance sedative, psychomotor, respiratory, and other effects of CNS depressant drugs and alcohol.<sup>1,2,3,4,5,6,7</sup> Use of only cannabidiol, another cannabinoid constituent of cannabis that has much lower or no psychoactivity, did not exert these effects or enhance them in combination with alcohol in a clinical study of healthy volunteers.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Reisfield GM. Medical cannabis and chronic opioid therapy. <i>J Pain Palliat Care Pharmacother</i>. 2010;24(4):356-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21133743\">[PubMed 21133743]</a></p>\n<p>2. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. <i>Accid Anal Prev</i>. 2010;42(6):1855-1865. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20728636\">[PubMed 20728636]</a></p>\n<p>3. Siemens AJ. Effects of cannabis in combination with ethanol and other drugs. <i>NIDA Res Monogr</i>. 1980;31:167-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106899\">[PubMed 6106899]</a></p>\n<p>4. Hollister LE. Interactions of cannabis with other drugs in man. <i>NIDA Res Monogr</i>. 1986;68:110-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095648\">[PubMed 3095648]</a></p>\n<p>5. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. <i>Psychopharmacology (Berl)</i>. 1994;115(3):340-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7871074\">[PubMed 7871074]</a></p>\n<p>6. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. <i>Anesthesiology</i>. 1975;42(6):674-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48348\">[PubMed 48348]</a></p>\n<p>7. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. <i>Alcohol Clin Exp Res</i>. 1988;12(2):268-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2837105\">[PubMed 2837105]</a></p>\n<p>8. Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. <i>Psychopharmacology (Berl)</i>. 1979;66(1):45-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=120541\">[PubMed 120541]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8280":"<p><b>Title</b> Alcohol (Ethyl) / Cannabis</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is only expected when physiologically significant amounts of tetrahydrocannabinol (THC, the major known psychoactive component of cannabis) are introduced systemically. While this encompasses the vast majority of medical and recreational cannabis use, some cannabis strains, products, and routes of administration specifically (and often intentionally) minimize systemic THC exposure.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cannabis may enhance the CNS depressant effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use cannabis concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants. These effects are likely largely or exclusively due to tetrahydrocannabinol (THC), and thus are not anticipated with the use of cannabis strains/products/uses that do not introduce substantial systemic THC concentrations.</p> \n<p><b>Discussion</b> Numerous published studies indicate that acute use of cannabis or tetrahydrocannabinol (THC, the primary known psychoactive component of cannabis) can enhance sedative, psychomotor, respiratory, and other effects of CNS depressant drugs and alcohol.<sup>1,2,3,4,5,6,7</sup> Use of only cannabidiol, another cannabinoid constituent of cannabis that has much lower or no psychoactivity, did not exert these effects or enhance them in combination with alcohol in a clinical study of healthy volunteers.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Reisfield GM. Medical cannabis and chronic opioid therapy. <i>J Pain Palliat Care Pharmacother</i>. 2010;24(4):356-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21133743\">[PubMed 21133743]</a></p>\n<p>2. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. <i>Accid Anal Prev</i>. 2010;42(6):1855-1865. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20728636\">[PubMed 20728636]</a></p>\n<p>3. Siemens AJ. Effects of cannabis in combination with ethanol and other drugs. <i>NIDA Res Monogr</i>. 1980;31:167-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106899\">[PubMed 6106899]</a></p>\n<p>4. Hollister LE. Interactions of cannabis with other drugs in man. <i>NIDA Res Monogr</i>. 1986;68:110-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095648\">[PubMed 3095648]</a></p>\n<p>5. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. <i>Psychopharmacology (Berl)</i>. 1994;115(3):340-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7871074\">[PubMed 7871074]</a></p>\n<p>6. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. <i>Anesthesiology</i>. 1975;42(6):674-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48348\">[PubMed 48348]</a></p>\n<p>7. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. <i>Alcohol Clin Exp Res</i>. 1988;12(2):268-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2837105\">[PubMed 2837105]</a></p>\n<p>8. Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. <i>Psychopharmacology (Berl)</i>. 1979;66(1):45-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=120541\">[PubMed 120541]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8281":"<p><b>Title</b> CNS Depressants / Tetrahydrocannabinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tetrahydrocannabinol may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use tetrahydrocannabinol concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for tetrahydrocannabinol and cannabidiol oromucosal spray warns that its use in patients receiving CNS depressant drugs may result in additive CNS depressant effects.<sup>1</sup> Numerous published studies indicate that acute use of cannabis or tetrahydrocannabinol (THC, the primary known psychoactive component of cannabis) can enhance sedative, psychomotor, respiratory, and other effects of CNS depressant drugs and alcohol.<sup>2,3,4,5,6,7,8</sup> Use of only cannabidiol, another cannabinoid constituent of cannabis that has much lower or no psychoactivity, did not exert these effects or enhance them in combination with alcohol in a clinical study of healthy volunteers.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [product monograph]. Toronto, ON: Bayer Inc; March 2012.</p>\n<p>2. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. <i>Accid Anal Prev</i>. 2010;42(6):1855-1865. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20728636\">[PubMed 20728636]</a></p>\n<p>3. Siemens AJ. Effects of cannabis in combination with ethanol and other drugs. <i>NIDA Res Monogr</i>. 1980;31:167-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106899\">[PubMed 6106899]</a></p>\n<p>4. Hollister LE. Interactions of cannabis with other drugs in man. <i>NIDA Res Monogr</i>. 1986;68:110-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095648\">[PubMed 3095648]</a></p>\n<p>5. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. <i>Psychopharmacology (Berl)</i>. 1994;115(3):340-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7871074\">[PubMed 7871074]</a></p>\n<p>6. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. <i>Anesthesiology</i>. 1975;42(6):674-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48348\">[PubMed 48348]</a></p>\n<p>7. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. <i>Alcohol Clin Exp Res</i>. 1988;12(2):268-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2837105\">[PubMed 2837105]</a></p>\n<p>8. Reisfield GM. Medical cannabis and chronic opioid therapy. <i>J Pain Palliat Care Pharmacother</i>. 2010;24(4):356-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21133743\">[PubMed 21133743]</a></p>\n<p>9. Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. <i>Psychopharmacology (Berl)</i>. 1979;66(1):45-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=120541\">[PubMed 120541]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8282":"<p><b>Title</b> Alcohol (Ethyl) / Tetrahydrocannabinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tetrahydrocannabinol may enhance the CNS depressant effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use tetrahydrocannabinol concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants.</p> \n<p><b>Discussion</b> The Canadian product monograph for tetrahydrocannabinol and cannabidiol oromucosal spray warns that its use in patients receiving CNS depressant drugs may result in additive CNS depressant effects.<sup>1</sup> Numerous published studies indicate that acute use of cannabis or tetrahydrocannabinol (THC, the primary known psychoactive component of cannabis) can enhance sedative, psychomotor, respiratory, and other effects of CNS depressant drugs and alcohol.<sup>2,3,4,5,6,7,8</sup> Use of only cannabidiol, another cannabinoid constituent of cannabis that has much lower or no psychoactivity, did not exert these effects or enhance them in combination with alcohol in a clinical study of healthy volunteers.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [product monograph]. Toronto, ON: Bayer Inc; March 2012.</p>\n<p>2. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. <i>Accid Anal Prev</i>. 2010;42(6):1855-1865. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20728636\">[PubMed 20728636]</a></p>\n<p>3. Siemens AJ. Effects of cannabis in combination with ethanol and other drugs. <i>NIDA Res Monogr</i>. 1980;31:167-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106899\">[PubMed 6106899]</a></p>\n<p>4. Hollister LE. Interactions of cannabis with other drugs in man. <i>NIDA Res Monogr</i>. 1986;68:110-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095648\">[PubMed 3095648]</a></p>\n<p>5. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. <i>Psychopharmacology (Berl)</i>. 1994;115(3):340-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7871074\">[PubMed 7871074]</a></p>\n<p>6. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. <i>Anesthesiology</i>. 1975;42(6):674-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48348\">[PubMed 48348]</a></p>\n<p>7. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. <i>Alcohol Clin Exp Res</i>. 1988;12(2):268-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2837105\">[PubMed 2837105]</a></p>\n<p>8. Reisfield GM. Medical cannabis and chronic opioid therapy. <i>J Pain Palliat Care Pharmacother</i>. 2010;24(4):356-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21133743\">[PubMed 21133743]</a></p>\n<p>9. Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. <i>Psychopharmacology (Berl)</i>. 1979;66(1):45-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=120541\">[PubMed 120541]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8283":"<p><b>Title</b> CNS Depressants / Dronabinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dronabinol may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use dronabinol concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Dronabinol U.S. prescribing information warns that its use in patients receiving CNS depressant drugs may result in additive CNS depressant effects.<sup>1</sup> Numerous published studies indicate that acute use of cannabis or tetrahydrocannabinol (THC, the primary known psychoactive component of cannabis, of which dronabinol is one isomer) can enhance sedative, psychomotor, respiratory, and other effects of CNS depressant drugs and alcohol.<sup>2,3,4,5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Marinol</i> (dronabinol) [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc; July 2006.</p>\n<p>2. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. <i>Accid Anal Prev</i>. 2010;42(6):1855-1865. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20728636\">[PubMed 20728636]</a></p>\n<p>3. Siemens AJ. Effects of cannabis in combination with ethanol and other drugs. <i>NIDA Res Monogr</i>. 1980;31:167-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106899\">[PubMed 6106899]</a></p>\n<p>4. Hollister LE. Interactions of cannabis with other drugs in man. <i>NIDA Res Monogr</i>. 1986;68:110-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095648\">[PubMed 3095648]</a></p>\n<p>5. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. <i>Psychopharmacology (Berl)</i>. 1994;115(3):340-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7871074\">[PubMed 7871074]</a></p>\n<p>6. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. <i>Anesthesiology</i>. 1975;42(6):674-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48348\">[PubMed 48348]</a></p>\n<p>7. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. <i>Alcohol Clin Exp Res</i>. 1988;12(2):268-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2837105\">[PubMed 2837105]</a></p>\n<p>8. Reisfield GM. Medical cannabis and chronic opioid therapy. <i>J Pain Palliat Care Pharmacother</i>. 2010;24(4):356-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21133743\">[PubMed 21133743]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8284":"<p><b>Title</b> Alcohol (Ethyl) / Dronabinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dronabinol may enhance the CNS depressant effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use dronabinol concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants.</p> \n<p><b>Discussion</b> Dronabinol U.S. prescribing information warns that its use in patients receiving CNS depressant drugs may result in additive CNS depressant effects.<sup>1</sup> Numerous published studies indicate that acute use of cannabis or tetrahydrocannabinol (THC, the primary known psychoactive component of cannabis, of which dronabinol is one isomer) can enhance sedative, psychomotor, respiratory, and other effects of CNS depressant drugs and alcohol.<sup>2,3,4,5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Marinol</i> (dronabinol) [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc; July 2006.</p>\n<p>2. Ronen A, Chassidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. <i>Accid Anal Prev</i>. 2010;42(6):1855-1865. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20728636\">[PubMed 20728636]</a></p>\n<p>3. Siemens AJ. Effects of cannabis in combination with ethanol and other drugs. <i>NIDA Res Monogr</i>. 1980;31:167-198. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106899\">[PubMed 6106899]</a></p>\n<p>4. Hollister LE. Interactions of cannabis with other drugs in man. <i>NIDA Res Monogr</i>. 1986;68:110-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3095648\">[PubMed 3095648]</a></p>\n<p>5. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. <i>Psychopharmacology (Berl)</i>. 1994;115(3):340-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7871074\">[PubMed 7871074]</a></p>\n<p>6. Johnstone RE, Lief PL, Kulp RA, Smith TC. Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics. <i>Anesthesiology</i>. 1975;42(6):674-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48348\">[PubMed 48348]</a></p>\n<p>7. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. <i>Alcohol Clin Exp Res</i>. 1988;12(2):268-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2837105\">[PubMed 2837105]</a></p>\n<p>8. Reisfield GM. Medical cannabis and chronic opioid therapy. <i>J Pain Palliat Care Pharmacother</i>. 2010;24(4):356-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21133743\">[PubMed 21133743]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8285":"<p><b>Title</b> CNS Depressants / Nabilone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nabilone may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use nabilone concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Nabilone U.S. prescribing information warns that its use in patients receiving CNS depressant drugs may result in additive CNS depressant effects.<sup>1</sup> In a clinical study of 15 healthy volunteers, coadministration of nabilone with diazepam, secobarbital, alcohol, or codeine resulted in additive depressant effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cesamet</i> (nabilone) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals International; May 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8286":"<p><b>Title</b> Alcohol (Ethyl) / Nabilone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nabilone may enhance the CNS depressant effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced CNS depressant effects in patients who use nabilone concomitantly with CNS depressant drugs or alcohol. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants.</p> \n<p><b>Discussion</b> Nabilone U.S. prescribing information warns that its use in patients receiving CNS depressant drugs may result in additive CNS depressant effects.<sup>1</sup> In a clinical study of 15 healthy volunteers, coadministration of nabilone with diazepam, secobarbital, alcohol, or codeine resulted in additive depressant effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cesamet</i> (nabilone) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals International; May 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8287":"<p><b>Title</b> FLUoxetine / Cannabinoid-Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cannabinoid-Containing Products may enhance the adverse/toxic effect of FLUoxetine. Specifically, the risk of a hypomanic episode may be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Cannabinoid-Containing Products Interacting Members</b> Cannabidiol, Cannabis, Dronabinol, Nabilone, Tetrahydrocannabinol</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for dronabinol and nabilone products summarizes a published case report in which a 21 year old woman with depression and bulimia treated with fluoxetine (20 mg/day) developed hypomanic symptoms after smoking marijuana.<sup>1,2,3</sup> Symptoms resolved within 4 days. <br><br>It is not clear whether the symptoms described in the case report were caused by an interaction between fluoxetine and cannabis. No similar reports have been published, and no similar symptoms were described in a 12 week clinical study in which 34 patients less than 25 years old were given fluoxetine for comorbid depression and cannabis use disorder.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cesamet</i> (nabilone) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals International; May 2006.</p>\n<p>2. <i>Marinol</i> (dronabinol) [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc; July 2006.</p>\n<p>3. Stoll AL, Cole JO, Lukas SE. A case of mania as a result of fluoxetine-marijuana interaction. <i>J Clin Psychiatry</i>. 1991;52(6):280-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1647392\">[PubMed 1647392]</a></p>\n<p>4. Cornelius JR, Bukstein OG, Douaihy AB, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. <i>Drug Alcohol Depend</i>. 2010;112(1-2):39-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20576364\">[PubMed 20576364]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8288":"<p><b>Title</b> Cannabinoid-Containing Products / Disulfiram</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Use of the dronabinol oral solution with disulfiram is contraindicated, but this interaction does not apply to the dronabinol capsules or other cannabinoid-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Disulfiram may enhance the adverse/toxic effect of Cannabinoid-Containing Products. Specifically, the risk of a hypomanic episode may be increased. Disulfiram may also produce intolerance to the alcohol contained in the dronabinol oral solution. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required for most of these combinations. Use of the dronabinol oral solution within 14 days of using disulfiram is contraindicated. Discontinue disulfiram at least 14 days prior to initiating dronabinol oral solution, and do not administer disulfiram within 7 days of stopping dronabinol oral solution. This specific contraindication is specific to the oral solution and does not apply to the dronabinol capsules.</p>\n<div>\n <p><b>Cannabinoid-Containing Products Interacting Members</b> Cannabidiol, Cannabis, Dronabinol, Nabilone, Tetrahydrocannabinol</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for dronabinol and nabilone products summarizes a published case report in which a 28 year old man reproducibly experienced hypomanic episodes after smoking marijuana during treatment with disulfiram.<sup>1,2,3</sup> Another very brief published case report describes similar symptoms developing in a 36 year old man who smoked cannabis during disulfiram treatment.<sup>4</sup> It is not presently clear whether the symptoms described in these case reports may have been caused by an interaction between disulfiram and cannabis. There is no known mechanism by which disulfiram would be expected to increase the likelihood of hypomania following cannabis use.<br><br>A separate interaction exists between disulfiram and dronabinol oral solution. The dronabinol oral solution contains 50% (w/w) alcohol and 5.5% (w/w) propylene glycol, both of which may interact with disulfiram to produce effects such as significant nausea and vomiting, abdominal pain, headache, and flushing.<sup>5</sup> As a result, concurrent use of the dronabinol oral solution within 14 days of disulfiram is contraindicated. The dronabinol capsules are not expected to share this specific interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cesamet (nabilone) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals International; May 2006.</p>\n<p>2. Marinol (dronabinol) capsules [prescribing information]. Marietta, GA: Unimed Pharmaceuticals, Inc; July 2006.</p>\n<p>3. Lacoursiere RB, Swatek R. Adverse interaction between disulfiram and marijuana: a case report. <i>Am J Psychiatry</i>. 1983;140(2):243-244. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6295192\">[PubMed 6295192]</a></p>\n<p>4. Mackie J, Clark D. Cannabis toxic psychosis while on disulfiram. <i>Br J Psychiatry</i>. 1994;164(3):421. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8199803\">[PubMed 8199803]</a></p>\n<p>5. Syndros (dronabinol) oral solution [prescribing information]. Chandler, AZ: Insys Therapeutics, Inc.; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8289":"<p><b>Title</b> Warfarin / Cannabinoid-Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cannabinoid-Containing Products may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Cannabinoid-Containing Products Interacting Members</b> Cannabidiol, Cannabis, Dronabinol, Nabilone, Tetrahydrocannabinol</p>\n</div> \n<p><b>Discussion</b> A single published case report describes a 56 year old man with multiple comorbidities (coronary artery disease with recent stent placement, peripheral vascular disease, seizure disorder, and gastroesophageal reflux) receiving warfarin in combination with several other drugs (aspirin, carbamazepine, clopidogrel, furosemide, metoprolol, omeprazole, potassium chloride, sertraline, tramadol, valproic acid), who also smoked tobacco and marijuana regularly, whose INR increased on 2 occasions from desired or subtherapeutic values (3.3 or 1.9 for the first and second episodes, respectively) to values over 10 within less than a week.<sup>1</sup> Both episodes were associated with bleeding (the first with a large melenic stool and hemoglobin 6.6 g/dL, and the second with a persistent nosebleed but hemoglobin 13.9 g/dL), and INR normalized in both cases following vitamin K doses with warfarin, aspirin, and clopidogrel withheld. <br><br>The reasons for the reported INR increases and bleeding episodes in the above case are not clear. Only in the second episode had the patient's warfarin dose recently increased, and that increase was less than 10%. The patient did not report any change in his other medications or diet, but did report that his amount and frequency of marijuana smoking had been elevated during the period including the 2 hospital admissions. The exact time course of his increase in usage is not clear, and there is no known mechanism by which marijuana or any of its components would be expected to increase warfarin exposure and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and marijuana smoking. <i>Ann Pharmacother</i>. 2009;43(7):1347-1353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19531696\">[PubMed 19531696]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8291":"<p><b>Title</b> Exemestane / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of estrogen derivatives in patients receiving exemestane.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> Exemestane U.S. prescribing information warns that it should not be coadministered with estrogen-containing agents due to a potential for such agents to interfere with exemestane therapeutic effects.<sup>1</sup> Exemestane is suspected to act primarily via inhibition of aromatase mediated conversion of androgens to estrogens.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aromasin</i> (exemestane) [prescribing information]. New York, NY: Pfizer Inc; February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8292":"<p><b>Title</b> Mipomersen / Lomitapide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lomitapide may enhance the hepatotoxic effect of Mipomersen. Specifically, the risk of steatosis may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of lomitapide and mipomersen.</p> \n<p><b>Discussion</b> Both mipomersen and lomitapide decrease LDL cholesterol but can increase hepatic fat. U.S. prescribing information for both products states that coadministration with other such agents is not recommended, as the impact of combination treatment has not been investigated but may further increase the risk of steatosis.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Juxtapid</i> (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc; February 2014.</p>\n<p>2. <i>Kynamro</i> (mipomersen) [prescribing information]. Cambridge, MA: Genzyme Corporation; January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8293":"<p><b>Title</b> Opioid Analgesics / Naltrexone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Naltrexone may diminish the therapeutic effect of Opioid Analgesics. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Seek therapeutic alternatives to opioids in patients receiving naltrexone. Patients may be less sensitive to opioid effects during naltrexone treatment, and should not attempt to overcome this by increasing doses. Conversely, patients may be more sensitive to opioid effects and require lower doses following naltrexone discontinuation. Counsel patients about these risks. Avoid the use of naltrexone/bupropion for weight management in patients receiving long-term opioid treatment or in patients with evidence of opioid withdrawal; use under these circumstances is listed as contraindicated in naltrexone/bupropion US prescribing information. The naltrexone/bupropion combination product should also be temporarily discontinued in patients requiring intermittent opioid treatment, and reintroduced only after 7-10 days have passed since the last opioid dose.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> The use of naltrexone-containing products is expected to diminish the therapeutic effects of opioids.<sup>1,2</sup> Patients may also be more sensitive to opioid effects following discontinuation of naltrexone.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Vivitrol</i> (naltrexone) [prescribing information]. Waltham, MA: Alkermes Inc; October 2010.</p>\n<p>2. <i>Contrave</i> (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8294":"<p><b>Title</b> Erythromycin (Systemic) / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fluconazole may enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of fluconazole and systemic erythromycin. Fluconazole U.S. prescribing information specifically lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Fluconazole U.S. prescribing information specifically lists its combination with erythromycin as contraindicated.<sup>1</sup> While no clinical data characterizing the potential interaction between these agents have been published, fluconazole is expected to increase erythromycin systemic concentrations (principally via inhibition of its CYP3A mediated metabolism) and may enhance its QTc prolonging effects based both on the expected pharmacokinetic interaction and on its independent QTc prolonging effects. Additionally, in one published review of several European health record databases, both fluconazole and erythromycin were identified as potentially associated with an increased risk of acute myocardial infarction.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p>2. Coloma PM, Schuemie MJ, Trifiro G, et al; EU-ADR Consortium. Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system. <i>PLoS One</i>. 2013;8(8):e72148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24015213\">[PubMed 24015213]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8295":"<p><b>Title</b> Simvastatin / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Two published case reports describe patients treated with simvastatin who developed rhabdomyolysis shortly after receiving treatment with ciprofloxacin.<sup>1,2</sup> In one, a 41-year-old female receiving chronic simvastatin (10 mg/day), amlodipine, and many other medications developed rhabdomyolysis one day after completing a four days of ciprofloxacin (500 mg twice daily) for peritoneal dialysis-related peritonitis.<sup>1</sup> Although the time course of rhabdomyolysis may point to the recent addition of antibiotics (ciprofloxacin, vancomycin, and gentamicin), the exact cause is unknown. Another published case report describes a 77-year-old female who had been taking simvastatin 40 mg/day and developed apparent rhabdomyolysis shortly after being started on ciprofloxacin for treatment of a urinary tract infection.<sup>2</sup> The authors of this case ascribe her rhabdomyolysis to an interaction of simvastatin with the ciprofloxacin, though the authors acknowledge that ciprofloxacin is not likely to significantly alter the metabolism of simvastatin. While this case could indeed represent an interaction where ciprofloxacin minimally increased simvastatin concentrations through a minor inhibition of CYP3A, resulting in toxicity for this patient, it is very unlikely that this combination would be of any significant concern for most other patients. Of note, the patient in this case had several risk factors predisposing her to such a toxicity, such as higher simvastatin dose, concurrent use of cimetidine (which is more likely to inhibit simvastatin metabolism than is ciprofloxacin), older age, and female sex, thus a small change in simvastatin concentration may be all that was required in her, whereas most other patients would not be expected to be similarly impacted.<br><br>It is also important to consider, however, that the rhabdomyolysis in this case may be due to factors other than such a ciprofloxacin-simvastatin interaction. Simvastatin and ciprofloxacin have each been associated with rhabdomyolysis (i.e., as causative agents), and either could have caused or contributed to this independently or additively (via something other than a pharmacokinetic interaction). Several reports have detailed adverse musculoskeletal effects of ciprofloxacin.<sup>3,4,5,6</sup> Further, the degree to infection and any associated dehydration, etc. could have contributed to the toxicity was not discussed in either case report.</p> \n<p><b>Footnotes</b> </p>\n<p>1. De Schryver N, Wittebole X, Van den Bergh P, Haufroid V, Goffin E, Hantson P. Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration. <i>Case Rep Nephrol</i>. 2015;2015:761393. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25883814\">[PubMed 25883814]</a></p>\n<p>2. Sawant RD. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. <i>Can J Clin Pharmacol</i>. 2009;16(1):e78-79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19151423\">[PubMed 19151423]</a></p>\n<p>3. Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. <i>Intern Med</i>. 2011;50(8):845-853. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21498932\">[PubMed 21498932]</a></p>\n<p>4. Alkhateeb H, Said S, Cooper CJ, Gaur S, Porres-Aguilar M. DRESS syndrome following ciprofloxacin exposure: An unusual association. <i>Am J Case Rep</i>. 2013;14:526-528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24340128\">[PubMed 24340128]</a></p>\n<p>5. Qian Q, Nasr SH, Akogyeram CO, Sethi S. Myoglobin-associated acute kidney injury in the setting of ciprofloxacin administration. <i>Am J Kidney Dis</i>. 2012;59(3):462-466. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22261117\">[PubMed 22261117]</a></p>\n<p>6. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. <i>Drug Saf</i>. 2003;26(2):109-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12534327\">[PubMed 12534327]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8296":"<p><b>Title</b> Apremilast / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The use of apremilast together with any strong CYP3A4 inducers is not recommended. The use of such a combination may result in diminished effectiveness of apremilast.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The apremilast AUC and maximum serum concentration (Cmax) were reduced by an average of 72% and 43%, respectively, when rifampin (a strong CYP3A4 inducer) 600 mg once daily (for 15 days) was administered with a single dose of apremilast 30 mg.<sup>1,2</sup><br><br>The likely mechanism of this interaction is increased CYP3A-mediated metabolism of apremilast due to the CYP3A4 inducing effects of rifampin. This is supported by the finding that rifampin administration was associated with an average 3.6-fold increase in the clearance of apremilast.<sup>1</sup> Similar effects are expected with other strong enzyme inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu Y, Zhou S, Wan Y, Wu A, Palmisano M. The impact of co-administration of ketoconazole and rifampin on the pharmacokinetics of apremilast in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2014; Jun 24 (Epub ahead of print). doi: 10.1111/bcp.12448. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24962564\">[PubMed 24962564]</a></p>\n<p>2. <i>Otezla</i> (apremilast) [Prescribing information]. Summit, NJ: Celgene Corporation, March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8297":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding St Johns wort in order to avoid therapeutic failure of the substrate. Some combinations are specifically contraindicated by manufacturers. Please review applicable prescribing information. Monitor for decreased effects of the CYP substrate if St Johns wort is initiated/dose increased, and increased effects if St Johns wort is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzhydrocodone, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etizolam, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zolpidem, Zonisamide, Zopiclone</p>\n</div> \n<p><b>Discussion</b> St Johns wort is expected to increase the metabolism of the drugs dependent on CYP3A-mediated metabolism. Substrate clearance would increase and serum concentrations would decrease. Decreased effects of the substrates would be expected. Several case reports and clinicial studies have demonstrated such effects with a variety of different CYP3A substrates, as described in several reviews on the subject.<sup>1,2,3</sup><br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant decrease in serum concentration of the substrate (ie, &gt;50%) could result in clinically relevant pharmacodynamic effects. St Johns wort is generally considered to be a “strong” inducer, though a highly variable one, because it has been shown to cause significant increases in CYP activity, and, therefore, significant increases in the clearance of drugs metabolized by this pathway.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. <i>Drugs</i>. 2009;69(13):1777-1798. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19719333\">[PubMed 19719333]</a></p>\n<p>2. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. <i>Curr Pharm Des</i>. 2008;14(17):1723-1742. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18673195\">[PubMed 18673195]</a></p>\n<p>3. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. <i>Curr Drug Metab</i>. 2008;9(5):394-409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18537576\">[PubMed 18537576]</a></p>\n<p>4. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p>5. U.S. Food and Drug Administration, “Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and LabelingRecommendations,” http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (accessed March 18, 2013).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8298":"<p><b>Title</b> Ibrutinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of ibrutinib and St John's wort is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 17 healthy volunteers, rifampin (600 mg daily for 10 days) decreased the ibrutinib (560 mg single dose given on day 8) maximum serum concentration and AUC 92% and 90%, respectively.<sup>1</sup> Additionally, a physiologically based pharmacokinetic modeling study predicted a possible 80% reduction in ibrutinib AUC with the strong CYP3A4 inducer carbamazepine and a possible 60% reduction in ibrutinib AUC with the moderate CYP3A inducer efavirenz.<sup>2</sup> <br><br>Ibrutinib prescribing information states that because CYP3A4 inducers can reduce ibrutinib efficacy, concomitant use of ibrutinib and St John's wort is not recommended.<sup>3</sup><br><br>The mechanism of this interaction is likely induction of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. <i>Clin Pharmacol Ther</i>. 2016;100(5):548-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27367453\">[PubMed 27367453]</a></p>\n<p>3. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8299":"<p><b>Title</b> Phenylephrine (Systemic) / Acetaminophen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetaminophen may increase the serum concentration of Phenylephrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients closely for increased side effects of phenylephrine if acetaminophen is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.</p> \n<p><b>Discussion</b> An average 2-fold increase in AUC and bioavailability and 4-fold increase in maximum serum concentration (Cmax) of phenylephrine was observed with the combination of 1000 mg acetaminophen and 10 mg phenylephrine in four randomized, open-label, cross-over studies where 90 healthy male volunteers received each of 10 treatment arms in a randomized order cross-over design. Treatment arms consisted of a combination of 1000 mg or 500 mg acetaminophen, 300 mg ibuprofen, and/or 10 mg or 5 mg phenylephrine.<sup>1,2</sup> Halving the phenylephrine dose to 5 mg taken concurrently with 1000 mg acetaminophen resulting in comparable pharmacokinetic profiles to 10 mg phenylephrine alone. Ibuprofen was excluded as a potential cause of increased phenylephrine concentrations as there was no significant change in phenylephrine pharmacokinetic parameters with the combination of ibuprofen and phenylephrine without acetaminophen. The study did not monitor blood pressure. A simulation attempting to predict what blood pressure effects should be expected following the observed 4-fold increase in phenylephrine Cmax with concurrent acetaminophen 1000 mg concluded that this magnitude of a change would result in an average 10 mmHg increase in mean arterial blood pressure.<sup>3</sup> However, it is important to emphasize that this represents only a simulation based on extrapolations from published data on phenylephrine concentrations and blood pressure changes after ophthalmic administration of phenylephrine.<sup>4</sup><br><br>Phenylephrine with acetaminophen has been described as safe in a phase III randomized, double-blinded, placebo-controlled controlled study testing the combination of 400 mg acetaminophen, 4 mg chlorphenamine, and 4 mg phenylephrine every 4 hours for 2-3 days among 146 subjects.<sup>5</sup> The side effect profile, including heart rate and blood pressure, were comparable in the treatment and placebo groups, though the phenylephrine and acetaminophen strengths were lower than those mentioned in the correspondence.<br><br>The proposed mechanism for this potential interaction is inhibition of phenylephrine sulfation in the intestinal wall by acetaminophen. Sulfation is a major metabolic pathway for phenylephrine, involving approximately 46% of the total phenylephrine parent drug.<sup>6</sup> An in vitro study showed that different acetaminophen doses decrease ethinyloestradiol sulfation by 32-80%, and although this study did not specifically involve phenylephrine, these findings suggest that this mechanism may explain the observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Atkinson HC, Stanescu I, Anderson BJ. Increased phenylephrine plasma levels with administration of acetaminophen. <i>N Engl J Med</i>. 2014;370(12):1171-1172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24645960\">[PubMed 24645960]</a></p>\n<p>2. Atkinson HC, Stanescu I, Salem II, Potts AL, Anderson BJ. Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 2015;71(2):151-158. [PubMed PMID: 25475358]</p>\n<p>3. Atkinson HC, Potts AL, Anderson BJ. Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. <i>Eur J Clin Pharmacol</i>. 2015;71(8):931-938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26022219\">[PubMed 26022219]</a></p>\n<p>4. Kumar V, Schoenwald RD, Chien DS, Packer AJ, Choi WW. Systemic absorption and cardiovascular effects of phenylephrine eyedrops. <i>Am J Ophthalmol</i>. 1985;99(2):180-184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3970123\">[PubMed 3970123]</a></p>\n<p>5. Picon PD, Costa MB, da Veiga Picon R, et al. Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial. <i>BMC Infect Dis</i>. 2013;13:556. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24261438\">[PubMed 24261438]</a></p>\n<p>6. Rogers SM, Back DJ, Orme ML. Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers. <i>Br J Clin Pharmacol</i>. 1987;23(6):727-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3606932\">[PubMed 3606932]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}